|
The
OncoEdge platform has set a new standard for Oncology
forecasting. It swiftly creates comprehensive
patient-based forecasts thereby addressing the inability of
companies to determine accurate estimates of treatable patient
populations. It provides flexible modeling capabilities that
allow companies to incorporate information related to
reimbursement, pricing and competitive market dynamics to create
forecasts that assess the impact of current and future market
conditions.
OncoEdge
has been used by our partner clients to derive forecasts for
products across a wide range of solid and hematologic tumours
representing hundred of millions of dollars in sales.
OncoEdge®
- A
KNOWLEDGE-BASED APPROACH
OncoEdge
forecasts are developed using a combination of information
inputs. The most critical components of OncoEdge are
the treatment algorithms used to generate the patient
populations. Treatment algorithms are used to
isolate the staging of patients, treatment options and/or
sub-stages and recurrence data in order to calculate
recurring patients populations.
SAI
treatment algorithms are created and validated by Key
Opinion Leaders from the North American oncology
community. The OncoEdge platform incorporates
feedback from more than 200 practitioners that are
recognized by their peers and the pharmaceutical industry
as Leaders nationally and internationally.
|
|
 |
OncoEdge®
- PREVALENCE:
THE HOLY GRAIL
Organizations
struggle with forecasts for Oncology agents since there is
no readily available source for prevalence numbers.
Newly incident patients numbers are readily available but
these offer a poor proxy. Many patient associations
offer data on survivorship but this also falls short of
filling the need.
OncoEdge
can easily and swiftly answer critical questions for
companies. Questions such as:
How
many patients will be treated with Stage IV 2nd line lung
cancer in 2012?
How
will changes in the treatment of RCC influence the number
of patients treated in 3rd line therapy in 2010?
What
impact will the wild KRAS gene have on colorectal cancer
treatment populations?
|
|
|
Addressing the
Evolution of Care in Oncology |
|
The
standards of care in Oncology are changing. More and more
oral medications are being introduced and these are being used
on a more chronic basis than previous therapies.
Supportive care agents need to assess market potential across a
variety of tumours. Further stratification within
treatment will occur as new genetic markers emerge and
treatments are specifically targeted to these markers.
OncoEdge
has been designed to address these needs in Oncology
forecasting. Our model also incorporates dynamic treatment
algorithms that represent both retrospective and prospective
standards of care.
The
Bottom Line
The
Strategic Planning process and the Annual Planning process in
most organizations can consume significant resources which could
be utilized to more effectively run the business. OncoAnswers
has developed an unmatched tool to streamline the:
Collection
of information
Dissemination
of information
Development
of consensus forecasts
|
Contact
Information:
Strategic
Answers Inc. 48 Wilgar Road, Toronto, Ontario
Phone: 416-604-4043
Fax: 905-823-5955
E-Mail:
Contact@StrategicAnswers.com
|
|
